Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Identifieur interne : 000343 ( Main/Exploration ); précédent : 000342; suivant : 000344Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Auteurs : J. Hinojosa [Espagne] ; J P Gisbert ; F. Gomoll N ; A. L Pez San RománSource :
- Journal of Crohn's & colitis [ 1876-4479 ] ; 2012.
Descripteurs français
- KwdFr :
- Adalimumab (MeSH), Adhésion aux directives (statistiques et données numériques), Anti-inflammatoires (usage thérapeutique), Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Azathioprine (usage thérapeutique), Enquêtes et questionnaires (MeSH), Espagne (MeSH), Gastroentérologie (normes), Gastroentérologie (statistiques et données numériques), Glucocorticoïdes (usage thérapeutique), Grippe humaine (prévention et contrôle), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Hépatite B (prévention et contrôle), Immunosuppresseurs (usage thérapeutique), Infliximab (MeSH), Maladie de Crohn (diagnostic), Maladie de Crohn (traitement médicamenteux), Méthotrexate (usage thérapeutique), Spécialisation (statistiques et données numériques), Vaccination (MeSH), Études prospectives (MeSH).
- MESH :
- diagnostic : Maladie de Crohn.
- normes : Gastroentérologie.
- prévention et contrôle : Grippe humaine, Hépatite B.
- statistiques et données numériques : Adhésion aux directives, Gastroentérologie, Spécialisation.
- traitement médicamenteux : Maladie de Crohn.
- usage thérapeutique : Anti-inflammatoires, Anticorps monoclonaux, Anticorps monoclonaux humanisés, Azathioprine, Glucocorticoïdes, Immunosuppresseurs, Méthotrexate.
- Adalimumab, Enquêtes et questionnaires, Espagne, Guides de bonnes pratiques cliniques comme sujet, Humains, Infliximab, Vaccination, Études prospectives.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adalimumab (MeSH), Anti-Inflammatory Agents (therapeutic use), Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Azathioprine (therapeutic use), Crohn Disease (diagnosis), Crohn Disease (drug therapy), Gastroenterology (standards), Gastroenterology (statistics & numerical data), Glucocorticoids (therapeutic use), Guideline Adherence (statistics & numerical data), Hepatitis B (prevention & control), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Infliximab (MeSH), Influenza, Human (prevention & control), Methotrexate (therapeutic use), Practice Guidelines as Topic (MeSH), Prospective Studies (MeSH), Spain (MeSH), Specialization (statistics & numerical data), Surveys and Questionnaires (MeSH), Vaccination (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Azathioprine, Glucocorticoids, Immunosuppressive Agents, Methotrexate.
- chemical : Adalimumab, Infliximab.
- geographic : Spain.
- diagnosis : Crohn Disease.
- drug therapy : Crohn Disease.
- prevention & control : Hepatitis B, Influenza, Human.
- standards : Gastroenterology.
- statistics & numerical data : Gastroenterology, Guideline Adherence, Specialization.
- Humans, Practice Guidelines as Topic, Prospective Studies, Surveys and Questionnaires, Vaccination.
Abstract
BACKGROUND
There is no information as to the extent by which Spanish gastroenterologists adhere to Crohn's disease (CD) management guidelines. The objective of this study was to evaluate the degree of adherence of Spanish gastroenterologists to the European Crohn's and Colitis Organisation (ECCO) guidelines and to determine whether differences in adherence exist between gastroenterologists specialized in inflammatory bowel diseases (GSIBDs) and general gastroenterologists (GGs).
METHODS
This was a prospective, nation-wide, questionnaire-based survey covering aspects related to diagnosis, treatment, follow-up, and safety considered by the physicians in their daily management of CD, as well as demographic traits seen in clinical practice.
RESULTS
The overall degree of adherence to guidelines by both GSIBDs and GGs was high. However, the use of imaging techniques in diagnosis, follow-up, and in relapsed patients differed between the two groups. In the diagnosis of perianal disease, GSIBDs used magnetic resonance and surgical exploration under anesthesia more frequently than GGs. In terms of therapeutic choices, the adherence to guidelines was good in both groups. However, GSIBDs showed significantly higher adherence in some areas: thiopurines were used less in refractory cases and methotrexate was used more commonly in corticoid-dependent, azathioprine-intolerant patients, and in patients under biological treatment. Request for infection studies and vaccinations at diagnosis or prior to treatment was more common among GSIBDs.
CONCLUSIONS
Guideline adherence among Spanish gastroenterologists is high. However, there are significant differences between IBD-specialized (more adherent in general) and non-specialized gastroenterologists.
DOI: 10.1016/j.crohns.2011.12.013
PubMed: 22398092
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.</title><author><name sortKey="Hinojosa, J" sort="Hinojosa, J" uniqKey="Hinojosa J" first="J" last="Hinojosa">J. Hinojosa</name><affiliation wicri:level="1"><nlm:affiliation>Departamento de Gastroenterología, Hospital de Manises, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Departamento de Gastroenterología, Hospital de Manises, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Gisbert, J P" sort="Gisbert, J P" uniqKey="Gisbert J" first="J P" last="Gisbert">J P Gisbert</name></author><author><name sortKey="Gomoll N, F" sort="Gomoll N, F" uniqKey="Gomoll N F" first="F" last="Gomoll N">F. Gomoll N</name></author><author><name sortKey="L Pez San Roman, A" sort="L Pez San Roman, A" uniqKey="L Pez San Roman A" first="A" last="L Pez San Román">A. L Pez San Román</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22398092</idno><idno type="pmid">22398092</idno><idno type="doi">10.1016/j.crohns.2011.12.013</idno><idno type="wicri:Area/Main/Corpus">00316</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00316</idno><idno type="wicri:Area/Main/Curation">000316</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000316</idno><idno type="wicri:Area/Main/Exploration">000316</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.</title><author><name sortKey="Hinojosa, J" sort="Hinojosa, J" uniqKey="Hinojosa J" first="J" last="Hinojosa">J. Hinojosa</name><affiliation wicri:level="1"><nlm:affiliation>Departamento de Gastroenterología, Hospital de Manises, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Departamento de Gastroenterología, Hospital de Manises, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Gisbert, J P" sort="Gisbert, J P" uniqKey="Gisbert J" first="J P" last="Gisbert">J P Gisbert</name></author><author><name sortKey="Gomoll N, F" sort="Gomoll N, F" uniqKey="Gomoll N F" first="F" last="Gomoll N">F. Gomoll N</name></author><author><name sortKey="L Pez San Roman, A" sort="L Pez San Roman, A" uniqKey="L Pez San Roman A" first="A" last="L Pez San Román">A. L Pez San Román</name></author></analytic><series><title level="j">Journal of Crohn's & colitis</title><idno type="eISSN">1876-4479</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (MeSH)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Azathioprine (therapeutic use)</term><term>Crohn Disease (diagnosis)</term><term>Crohn Disease (drug therapy)</term><term>Gastroenterology (standards)</term><term>Gastroenterology (statistics & numerical data)</term><term>Glucocorticoids (therapeutic use)</term><term>Guideline Adherence (statistics & numerical data)</term><term>Hepatitis B (prevention & control)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Infliximab (MeSH)</term><term>Influenza, Human (prevention & control)</term><term>Methotrexate (therapeutic use)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Prospective Studies (MeSH)</term><term>Spain (MeSH)</term><term>Specialization (statistics & numerical data)</term><term>Surveys and Questionnaires (MeSH)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab (MeSH)</term><term>Adhésion aux directives (statistiques et données numériques)</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Azathioprine (usage thérapeutique)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Espagne (MeSH)</term><term>Gastroentérologie (normes)</term><term>Gastroentérologie (statistiques et données numériques)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Grippe humaine (prévention et contrôle)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Hépatite B (prévention et contrôle)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infliximab (MeSH)</term><term>Maladie de Crohn (diagnostic)</term><term>Maladie de Crohn (traitement médicamenteux)</term><term>Méthotrexate (usage thérapeutique)</term><term>Spécialisation (statistiques et données numériques)</term><term>Vaccination (MeSH)</term><term>Études prospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Azathioprine</term><term>Glucocorticoids</term><term>Immunosuppressive Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adalimumab</term><term>Infliximab</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Maladie de Crohn</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Gastroentérologie</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Hépatite B</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Gastroenterology</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Gastroenterology</term><term>Guideline Adherence</term><term>Specialization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Adhésion aux directives</term><term>Gastroentérologie</term><term>Spécialisation</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Crohn</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Azathioprine</term><term>Glucocorticoïdes</term><term>Immunosuppresseurs</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Practice Guidelines as Topic</term><term>Prospective Studies</term><term>Surveys and Questionnaires</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adalimumab</term><term>Enquêtes et questionnaires</term><term>Espagne</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infliximab</term><term>Vaccination</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>There is no information as to the extent by which Spanish gastroenterologists adhere to Crohn's disease (CD) management guidelines. The objective of this study was to evaluate the degree of adherence of Spanish gastroenterologists to the European Crohn's and Colitis Organisation (ECCO) guidelines and to determine whether differences in adherence exist between gastroenterologists specialized in inflammatory bowel diseases (GSIBDs) and general gastroenterologists (GGs).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This was a prospective, nation-wide, questionnaire-based survey covering aspects related to diagnosis, treatment, follow-up, and safety considered by the physicians in their daily management of CD, as well as demographic traits seen in clinical practice.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The overall degree of adherence to guidelines by both GSIBDs and GGs was high. However, the use of imaging techniques in diagnosis, follow-up, and in relapsed patients differed between the two groups. In the diagnosis of perianal disease, GSIBDs used magnetic resonance and surgical exploration under anesthesia more frequently than GGs. In terms of therapeutic choices, the adherence to guidelines was good in both groups. However, GSIBDs showed significantly higher adherence in some areas: thiopurines were used less in refractory cases and methotrexate was used more commonly in corticoid-dependent, azathioprine-intolerant patients, and in patients under biological treatment. Request for infection studies and vaccinations at diagnosis or prior to treatment was more common among GSIBDs.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Guideline adherence among Spanish gastroenterologists is high. However, there are significant differences between IBD-specialized (more adherent in general) and non-specialized gastroenterologists.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22398092</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4479</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of Crohn's & colitis</Title><ISOAbbreviation>J Crohns Colitis</ISOAbbreviation></Journal><ArticleTitle>Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.</ArticleTitle><Pagination><MedlinePgn>763-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.crohns.2011.12.013</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is no information as to the extent by which Spanish gastroenterologists adhere to Crohn's disease (CD) management guidelines. The objective of this study was to evaluate the degree of adherence of Spanish gastroenterologists to the European Crohn's and Colitis Organisation (ECCO) guidelines and to determine whether differences in adherence exist between gastroenterologists specialized in inflammatory bowel diseases (GSIBDs) and general gastroenterologists (GGs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a prospective, nation-wide, questionnaire-based survey covering aspects related to diagnosis, treatment, follow-up, and safety considered by the physicians in their daily management of CD, as well as demographic traits seen in clinical practice.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall degree of adherence to guidelines by both GSIBDs and GGs was high. However, the use of imaging techniques in diagnosis, follow-up, and in relapsed patients differed between the two groups. In the diagnosis of perianal disease, GSIBDs used magnetic resonance and surgical exploration under anesthesia more frequently than GGs. In terms of therapeutic choices, the adherence to guidelines was good in both groups. However, GSIBDs showed significantly higher adherence in some areas: thiopurines were used less in refractory cases and methotrexate was used more commonly in corticoid-dependent, azathioprine-intolerant patients, and in patients under biological treatment. Request for infection studies and vaccinations at diagnosis or prior to treatment was more common among GSIBDs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Guideline adherence among Spanish gastroenterologists is high. However, there are significant differences between IBD-specialized (more adherent in general) and non-specialized gastroenterologists.</AbstractText><CopyrightInformation>Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hinojosa</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Gastroenterología, Hospital de Manises, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisbert</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Gomollón</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>López San Román</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Crohns Colitis</MedlineTA><NlmUniqueID>101318676</NlmUniqueID><ISSNLinking>1873-9946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005762" MajorTopicYN="N">Gastroenterology</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013038" MajorTopicYN="N">Specialization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22398092</ArticleId><ArticleId IdType="pii">S1873-9946(12)00002-5</ArticleId><ArticleId IdType="doi">10.1016/j.crohns.2011.12.013</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Gisbert, J P" sort="Gisbert, J P" uniqKey="Gisbert J" first="J P" last="Gisbert">J P Gisbert</name><name sortKey="Gomoll N, F" sort="Gomoll N, F" uniqKey="Gomoll N F" first="F" last="Gomoll N">F. Gomoll N</name><name sortKey="L Pez San Roman, A" sort="L Pez San Roman, A" uniqKey="L Pez San Roman A" first="A" last="L Pez San Román">A. L Pez San Román</name></noCountry><country name="Espagne"><noRegion><name sortKey="Hinojosa, J" sort="Hinojosa, J" uniqKey="Hinojosa J" first="J" last="Hinojosa">J. Hinojosa</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000343 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000343 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22398092
|texte= Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22398092" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |